Kezar Life Sciences Inc (KZR) Stock Price, Quote & News

Company Profile

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 822 5600

Website: www.kezarlifesciences.com

Address:

4000 Shoreline Court, Suite 300, South San Francisco, United States

CEMBP_Trader May. 13 at 12:55 AM

$KZR Shares gone, cash and CVR received. Let’s see what the CVR can return. 🍀🎉🍀

0 · Reply

nsomniyak May. 12 at 2:49 AM

$KZR Here's the payout timeline as I understand it. $6.95 cash per share - to be paid promptly - probably this week or next. cash CVR - pro-rata share of KZR net cash above $50MM - probably 3-4 months as AUPH wil need to audit KZR financials drug-related CVR - out in the fture if/when KZR's drug reaches certain milestones

0 · Reply

nsomniyak May. 12 at 2:10 AM

$KZR The buyout of KZR by AUPH was approved.

0 · Reply

TwongStocks May. 7 at 2:28 PM

$KZR Equity Corporate Actions Alert #2026 - 307 Information Regarding the Tender Offer of Kezar Life Sciences, Inc. (KZR) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-307 The tender offer by Aurinia Pharmaceuticals Inc. $AUPH to acquire all of the outstanding common stock of Kezar Life Sciences, Inc. $KZR is scheduled to expire at 11:59 p.m. ET, on May 8, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on May 11, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 8, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (May 11th) and will be suspended effective May 12, 2026. KZR shareholders will receive $6.955 & one non-transferable CVR for each share held.

0 · Reply

whatsup58 Apr. 23 at 9:48 PM

$KZR this is officially done now?

0 · Reply

STACKD0E Apr. 15 at 4:13 PM

$RVMD $KZR 🙃✨

0 · Reply

OfficialStocktwitsUser Apr. 13 at 11:14 PM

$KZR RSI: 77.78, MACD: 0.1963 Vol: 0.46, MA20: 6.98, MA50: 6.76 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

focafoca99 Apr. 3 at 9:37 PM

$KZR is paying about $2 million to exit its San Francisco lease early, including a $1.3 million cash payment and the loss of its $0.7 million security deposit.

0 · Reply

skyrockets_Inc Mar. 31 at 6:57 PM

$NEUP $KZR got deal two days ago, today is $APLS, next is $NEUP !

1 · Reply

financialhorizon Mar. 31 at 9:17 AM

$KZR — Acquisition Update 💰 Bought out at $6.955/share in cash + CVR At $6.20/share, upside was limited — this ~12% premium + CVR is better than expected for shareholders CVR priced at ~$0.50, which appears overly optimistic

1 · Reply

Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies

AUPH

2026-03-30T12:49:02.000Z - 6 weeks ago

Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR

AUPH

2026-03-30T12:27:13.000Z - 6 weeks ago

Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR

AUPH

Mar 30, 2026, 8:00 AM EDT - 6 weeks ago

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

AUPH

Mar 12, 2026, 9:00 AM EDT - 2 months ago

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences

2026-01-09T11:05:29.000Z - 4 months ago

Kezar Life Sciences: FDA grants Type C meeting to discuss zetomipzomib

Jan 9, 2026, 6:01 AM EST - 4 months ago

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

2025-11-12T21:05:17.000Z - 6 months ago

Kezar Life Sciences reports Q3 EPS ($1.53), consensus ($1.96)

Nov 12, 2025, 4:01 PM EST - 6 months ago

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

Nov 7, 2025, 7:01 AM EST - 6 months ago

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

2025-10-17T11:00:33.000Z - 7 months ago

Kezar Life Sciences price target lowered to $5 from $7 at Wells Fargo

2025-10-17T09:15:16.000Z - 7 months ago

Kezar downgraded to Market Perform from Outperform at William Blair

2025-10-17T08:50:11.000Z - 7 months ago

Kezar Life Sciences downgraded to Hold from Buy at Jefferies

2025-10-16T20:30:19.000Z - 7 months ago

Kezar Life Sciences trading resumes

2025-10-16T20:10:33.000Z - 7 months ago

Kezar says interim study required by FDA would delay future zetomipzomib trials

2025-10-16T20:10:27.000Z - 7 months ago

Kezar Life Sciences to explore strategic alternatives

2025-10-16T20:05:46.000Z - 7 months ago

Kezar Life Sciences trading halted, news pending

Oct 16, 2025, 4:05 PM EDT - 7 months ago

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

Aug 28, 2025, 4:01 PM EDT - 9 months ago

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

2025-08-13T20:05:48.000Z - 9 months ago

Kezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)

Aug 13, 2025, 4:01 PM EDT - 9 months ago

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-07-15T20:45:26.000Z - 10 months ago

Kezar Life Sciences lifts partial clinical hold on PORTOLA Phase 2a trial

Jul 15, 2025, 4:41 PM EDT - 10 months ago

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

Jun 4, 2025, 2:35 PM EDT - 1 year ago

Kezar Life Sciences Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 4:01 PM EDT - 1 year ago

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

2025-05-13T20:07:38.000Z - 1 year ago

Kezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65)

May 13, 2025, 4:01 PM EDT - 1 year ago

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

2025-03-26T10:25:47.000Z - 1 year ago

Kezar Life Sciences price target lowered to $7 from $9 at Wells Fargo

2025-03-25T18:44:32.000Z - 1 year ago

Kezar Life Sciences reports topline results from PORTOLA trial

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Kezar Life Sciences Earnings Call Transcript: Q4 2024

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Feb 18, 2025, 4:01 PM EST - 1 year ago

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

2025-02-05T22:25:07.000Z - 1 year ago

Kezar Life Sciences files $400M mixed securities shelf

Nov 12, 2024, 4:01 PM EST - 1 year ago

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Oct 17, 2024, 8:35 AM EDT - 1 year ago

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

Oct 17, 2024, 8:30 AM EDT - 1 year ago

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

Oct 4, 2024, 5:11 PM EDT - 1 year ago

US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial

Oct 4, 2024, 5:00 PM EDT - 1 year ago

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Sep 30, 2024, 8:46 AM EDT - 1 year ago

Kezar Life Sciences halts mid-stage trial for lupus treatment

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

Sep 4, 2024, 4:01 PM EDT - 1 year ago

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 4:02 PM EDT - 1 year ago

Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 10, 2024, 4:01 PM EDT - 2 years ago

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

May 9, 2024, 4:01 PM EDT - 2 years ago

Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 4:05 PM EDT - 2 years ago

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mar 14, 2024, 4:01 PM EDT - 2 years ago

Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Feb 28, 2024, 4:01 PM EST - 2 years ago

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 6:30 PM EST - 2 years ago

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Nov 21, 2023, 4:01 PM EST - 2 years ago

Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 4:01 PM EST - 2 years ago

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 3, 2023, 4:10 PM EDT - 2 years ago

Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

Sep 20, 2023, 6:30 PM EDT - 2 years ago

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

Sep 12, 2023, 10:50 AM EDT - 2 years ago

Kezar Life Sciences Transcript: Morgan Stanley 21st Annual Global Healthcare Conference

Aug 31, 2023, 4:01 PM EDT - 2 years ago

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

Aug 10, 2023, 4:01 PM EDT - 2 years ago

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

May 31, 2023, 7:00 AM EDT - 3 years ago

Kezar Life Sciences to Participate in the Jefferies Healthcare Conference

May 11, 2023, 4:01 PM EDT - 3 years ago

Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

Mar 15, 2023, 4:30 PM EDT - 3 years ago

Kezar Life Sciences Transcript: Kezar Life Sciences R&D Day 2023

Mar 14, 2023, 4:01 PM EDT - 3 years ago

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Mar 13, 2023, 7:00 AM EDT - 3 years ago

Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

Mar 6, 2023, 7:00 AM EST - 3 years ago

Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

Mar 1, 2023, 4:01 PM EST - 3 years ago

Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

Jan 11, 2023, 5:15 PM EST - 3 years ago

Kezar Life Sciences Transcript: 41st Annual J.P. Morgan Healthcare Conference

Jan 4, 2023, 4:01 PM EST - 3 years ago

Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 14, 2022, 7:00 AM EST - 3 years ago

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

CEMBP_Trader May. 13 at 12:55 AM

$KZR Shares gone, cash and CVR received. Let’s see what the CVR can return. 🍀🎉🍀

0 · Reply

nsomniyak May. 12 at 2:49 AM

0 · Reply

nsomniyak May. 12 at 2:10 AM

$KZR The buyout of KZR by AUPH was approved.

0 · Reply

TwongStocks May. 7 at 2:28 PM

0 · Reply

whatsup58 Apr. 23 at 9:48 PM

$KZR this is officially done now?

0 · Reply

STACKD0E Apr. 15 at 4:13 PM

$RVMD $KZR 🙃✨

0 · Reply

OfficialStocktwitsUser Apr. 13 at 11:14 PM

0 · Reply

focafoca99 Apr. 3 at 9:37 PM

$KZR is paying about $2 million to exit its San Francisco lease early, including a $1.3 million cash payment and the loss of its $0.7 million security deposit.

0 · Reply

skyrockets_Inc Mar. 31 at 6:57 PM

$NEUP $KZR got deal two days ago, today is $APLS, next is $NEUP !

1 · Reply

financialhorizon Mar. 31 at 9:17 AM

1 · Reply

CEMBP_Trader Mar. 30 at 2:33 PM

$KZR adding CVR for 30 cents / 4.2% 🍀🎉🍀

0 · Reply

aletz Mar. 30 at 2:02 PM

$KZR dead company, cash liquidation for institutions, AUPH just paying cash for cash + very slim chance of CVR profit

0 · Reply

topstockalerts Mar. 30 at 1:59 PM

$KZR okay this is getting interesting now 👀

0 · Reply

MRTunity Mar. 30 at 1:15 PM

$AUPH got a feeling Tang has a suitor lined up for AUPH but that suitor wanted $KZR as part of the package ‼️ long term leaps is the way to play this- no point of holding shares and taking up too much of your purchasing power

0 · Reply

notreload_ai Mar. 30 at 12:59 PM

$AUPH has agreed to acquire $KZR for $6.955 in cash per share plus a Contingent Value Right (CVR). https://notreload.xyz/aurinia-to-acquire-kezar-life-sciences/

0 · Reply

DARKP00L Mar. 30 at 12:33 PM

$KZR 08:25 on Mar. 30 2026 Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times #tradeideas

0 · Reply

bananastand1203 Mar. 30 at 12:30 PM

$SGMO If this company is being bought out, then asset sales will precede the acquisition. There are very few pharma who would want the entire portfolio given how diversified it is. Look at what happened with $KZR and that biotech had a significantly less diverse portfolio

0 · Reply

bryantboy99 Mar. 30 at 12:21 PM

$AUPH not much in the pipeline over at $KZR. https://kezarlifesciences.com/pipeline/zetomipzomib

0 · Reply

bryantboy99 Mar. 30 at 12:11 PM

$AUPH so how does $KZR pipeline fit with Aurinia?

0 · Reply

OpenOutcrier Mar. 30 at 12:08 PM

$KZR (halted pre) $AUPH Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right https://ooc.bz/l/97568

0 · Reply

TwongStocks Mar. 30 at 12:04 PM

$KZR Trading scheduled to resume at 8:30am ET

0 · Reply

Market Cap	53.86M
Revenue (ttm)	0.00
Net Income (ttm)	-56.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	616,000
Avg Vol	96,874
Day's Range	N/A - N/A
Shares Out	7.39M
Stochastic %K	25%
Beta	0.40
Analysts	Hold
Price Target	$6.00